Strategic Collaboration Tolmar is actively pursuing collaboration to commercialize Alpha DaRT for prostate cancer in the US alongside Alpha Tau Medical, signaling potential joint sales efforts, co-marketing opportunities, and access to Alpha DaRT's clinical and payer networks.

Patient Education The launch of education and support initiatives such as So They're on TRT...Now What? and a telemedicine program for JATENZO indicates opportunities to position Tolmar as a trusted partner for patient and clinician education, expanding outreach to urology and endocrinology segments.

Therapy Portfolio Tolmar’s focus on long-acting injectable therapies across urology, oncology, and endocrinology, plus recent acquisition of JATENZO and telemedicine access, suggests cross-sell potential to existing physician networks and specialty clinics treating male health, prostate cancer, and hormonal therapies.

Digital & Ops Readiness With an expanded tech stack including OpenAI, ServiceNow, DocuSign, and iCIMS, Tolmar appears equipped to streamline sales, clinical communications, and contract workflows, enabling scalable partner onboarding and faster deal cycles with health systems and specialty distributors.

Market Momentum Strong revenue band and international recognition in advanced drug delivery, plus ongoing patient access initiatives and leadership appointments, indicate a healthy growth trajectory ideal for entering new payer negotiations, channel partnerships, and regional expansion in North America.